Overall, OMP-52M51 was well tolerated, exhibiting moderate anti-tumor activity with one partial response (PR) and two stable disease (SD) in twenty-four lymphoid malignancies [29], two PR and four SD in thirty-six (17%) assessable patients with a solid tumor [30], and one PR of one patient with Notch1-mutant ACC [31]. This evidence concerns the gene NOTCH1 and neoplasm.